BofA analyst Jason Gerberry raised the firm’s price target on Oculis (OCS) to $30 from $28 and keeps a Buy rating on the shares after the company updated on its plans to start pivotal testing of privosegtor in acute optic neuritis and non-arteritic anterior ischemic optic neuropathy. Based on the update, the firm pushed out its U.S. launch assumption to 2028 from late 2027 given the anticipated enrollment timelines and raised its view on the probability of success for the AON program to 60% from 50% to reflect FDA alignment on a protocol. The firm continues to forecast $600M in nominal peak U.S. sales for privosegtor in AON, the analyst noted.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis price target raised to $36 from $33 at H.C. Wainwright
- Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology
- Oculis Holding: Strategic Advancements and Market Potential Drive Buy Rating
- Oculis initiated with a Buy at Needham
- Nvidia reportedly stops H20 AI chip output for China: Morning Buzz